middle.news
Biotron Advances Hepatitis B Drug After $1.27M Capital Raise
1:42pm on Tuesday 29th of July, 2025 AEST
•
Biotechnology
Read Story
Biotron Advances Hepatitis B Drug After $1.27M Capital Raise
1:42pm on Tuesday 29th of July, 2025 AEST
Key Points
Completed $1.27 million entitlement issue to fund operations
First stage animal safety study of lead Hepatitis B compound successfully completed
Ongoing commercialisation efforts supported by US-based C14 Consulting Group
Appointed Michael Medway as new Non-Executive Director post-quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE